Seattle Genetics Inc. (SGEN - Analyst Report) recently presented data on its antibody-drug conjugate (ADC) candidates at the annual meeting of the American Association for Cancer Research (AACR).
Preclinical data on SGN-CD33A showed significant antitumor activity in acute myeloid leukemia (AML) models. Seattle Genetics intends to file an investigational new drug (IND) application and start a phase I study in 2013.
Another candidate, SGN-LIV1A, showed encouraging pre-clinical data for breast cancer. Seattle Genetics will file an IND application for SGN-LIV1A as well and start a phase I study in 2013 for breast cancer.
Seattle Genetics’ sole marketed ADC product is Adcetris. Adcetris is used for the treatment of patients with Hodgkin's lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris is also approved for the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen.
Adcetris was approved by the US Food and Drug Administration (FDA) in Aug 2011, got EU approval in Oct 2012 and marketing authorization in Canada in Feb 2013.
ADCs have been attracting a lot of interest of late with major companies entering into collaborations. Seattle Genetics has collaborations with companies like Roche Holding AG's (RHHBY - Analyst Report) Genentech for the development of ADCs.
A few days back, Astellas Pharma, Inc. (ALPMY - Snapshot Report) announced a deal with Ambrx Inc. for the discovery and development of novel ADCs.
Seattle Genetics carries a Zacks Rank #3 (Hold). Right now Cleveland BioLabs, Inc. looks more attractive with a Zacks Rank #1 (Strong Buy).